

1

2 **Validation and Responsiveness of the English version of the Chemotherapy-Induced**
3 **Alopecia Distress Scale (CADS) in Breast Cancer Patients.**

4

5 **Authors:**

6 L. Kraehenbuehl,^{1,2°} D. Kang^{3,4°}, A. S. Bang¹, K. F. Ketosugbo¹, J. Hay⁵, Sujata Patil⁶, S.
7 Goldfarb¹, J. Cho^{3,4*}, and M. E. Lacouture^{1*}

8

9 **Affiliations**

10 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
11 USA

12 2. Department of Dermatology, University Hospital Zurich (USZ), University of Zurich
13 (UZH), Zurich, Switzerland

14 3 Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan
15 University, Seoul, Korea.

16 4 Center for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University
17 School of Medicine, Seoul, Korea.

18 5 Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer
19 Center, New York, New York, USA

20 6 Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA

21

22 ° shared first authors

23 *shared last authors

24 **Corresponding authors:**

25

26 Prof. Juhee Cho

27 Samsung Medical Center

28 50 Irwon-ro, Gangnam

29 Seoul 06351

30 Republic of Korea

31 +82-2-3410-1448

32 alfadur2j@gmail.com

1

1

2 Dr Lukas Kraehenbuehl

3 Department of Dermatology

4 University Hospital Zurich, University of Zurich

5 Raemistrasse 100

6 8091 Zurich

7 SWITZERLAND

8

9 +41442553155

10 Lukas.Kraehenbuehl@usz.ch

11

12

13

14

1 **Abstract:**

2 *Purpose:* This study aimed to validate the chemotherapy-induced alopecia distress scale
3 (CADS) in a diverse English-speaking population and patients with endocrine treatment-
4 induced alopecia (EIA). *Objective:* Chemotherapy and endocrine therapy commonly cause
5 alopecia in breast cancer patients, leading to significant psychological and social challenges.
6 The CADS was developed to assess the psychosocial impact of alopecia, but its
7 generalizability beyond Korean patients requires further investigation. *Methods:* Data from
8 the CHANCE study (NCT02530177), which focused on non-metastatic breast cancer, was
9 used. The cohort included 256 patients, and CADS data were collected at baseline, six
10 months after chemotherapy completion, or 12 months after initiating endocrine therapy. The
11 CADS questionnaire comprised 17 items covering physical and emotional health, daily
12 activities, and relationships. Reliability was assessed using Cronbach's alpha, and
13 responsiveness was measured by effect size. *Results:* The CADS exhibited good reliability,
14 with a Cronbach's alpha of 0.91 for the overall score, indicating acceptable internal
15 consistency in both chemotherapy (0.89) and endocrine therapy (0.86) groups. Longitudinal
16 responsiveness was supported by an effect size of 0.49 between decreasing satisfaction with
17 hair growth and increasing emotional distress. Cross-sectional validity was confirmed, with
18 effect sizes of 0.91 and 0.92 for satisfaction with hair growth and emotional and activity
19 domains, respectively. *Conclusion:* The CADS is a valid and responsive tool for assessing the
20 psychosocial impact of chemotherapy-induced alopecia and endocrine treatment-induced
21 alopecia in a diverse Western patient population.

22

23

24 **Acknowledgments**

25 Funding was provided by the RJR fund

1 NIH/NCI Cancer Center Support Grant P30 CA008748

2 Lukas Kraehenbuehl was also supported by the Swiss National Science Foundation
3 P400PM_199318.

4

5 **Declaration of Potential Conflicts of Interest**

6 LK, DK, KFK, ASB, JH, SG and JC declare no conflict of interest; SP is a consultant for
7 ByHeart, MEL: has a consultant role with Johnson and Johnson, Novocure, QED, Bicara,
8 Janssen, Novartis, F. Hoffmann-La Roche AG, EMD Serono, Astrazeneca, Innovaderm,
9 Deciphera, DFB, Azitra, Kintara, RBC/La Roche Posay, Trifecta, Varsona, Genentech, Loxo,
10 Seattle Genetics, Lutris, OnQuality, Azitra, Roche, Oncoderm, NCODA, Apricity. MEL also
11 receives research funding from Lutris, Paxman, Novocure, J&J, US Biotest, OQL, Novartis,
12 and AZ

13

14 Keywords:

- 15 - Alopecia
- 16 - Cancer
- 17 - Chemotherapy
- 18 - Endocrine Therapy
- 19 - Hair Loss
- 20 - Oncodermatology
- 21 - Oncology
- 22 - Patient Reported Outcome
- 23 - Supportive care
- 24 - Survivorship

25

1 **BACKGROUND**

2 Alopecia induced by cancer treatment can be one of breast cancer patients' most stressful and
3 burdensome adverse events. The incidence of alopecia in early-stage breast cancer patients
4 undergoing cytotoxic chemotherapy is expected to be above 80% with taxanes and 60-100%
5 with anthracyclines¹. Persistent chemotherapy-induced alopecia (pCIA) is defined as
6 incomplete hair regrowth six months after completion of chemotherapy and occurs in 39.5%
7 of breast cancer patients². Additionally, 22.4% and 31.8% of women undergoing adjuvant
8 endocrine therapy for breast cancer report hair loss and hair thinning, respectively¹. The
9 multi-faceted importance of CIA has recently been reviewed³, emphasizing the importance of
10 CIA as a representation of illness to the patient and the public.

11

12 Previous studies have shown that alopecia can affect treatment choice and dose intensity and
13 lead to early treatment discontinuation. Alopecia can cause disproportionate psychosocial
14 impairment, affecting patients' functional status, emotional well-being, and relationships with
15 others. It has been reported as the third most burdensome adverse event in treating
16 gynecological- and breast cancer.⁴⁻⁸ Patients with higher distress related to cancer treatment-
17 associated alopecia are 1.5 times more likely to suffer from depression than those with lower
18 distress⁹.

19 To our knowledge, the incidence of chemotherapy-associated alopecia in men and potential
20 ethnic or racial differences in women have not been studied in English literature. Further
21 research needs to be conducted to understand better the significance of ethnicity, gender, and
22 race in patients experiencing alopecia from cancer therapy. In most clinical trials, as well as
23 in routine oncological practice, grading of alopecia is based on the Common Terminology
24 Criteria for Adverse Events (CTCAE), distinguishing between no hair loss (grade 0), "hair

1 loss of <50% of normal for that individual that is not obvious from a distance but only on
2 close inspection; a different hairstyle may be required to cover the hair loss, but it does not
3 require a wig or hair piece to camouflage” (grade 1) and “hair loss of \geq 50% normal for that
4 individual that is readily apparent to others; a wig or hairpiece is necessary if the patient
5 desires to camouflage the hair loss completely; associated with psychosocial impact” (grade
6 2)¹⁰. In addition, a patient-reported outcome grading tool (PRO-CTCAE) is available as a
7 companion measurement. Patients are requested to quantify their hair loss during the last
8 seven days as ‘not at all’ (grade 0), ‘a little bit’ (grade 1), ‘somewhat’ (grade 2), ‘quite a bit’
9 (grade 3) and ‘very much’ (grade 4)¹¹. The CTCAE grading is well-recognized and easy to
10 use but does not capture the psychological impact of alopecia in cancer patients.

11 Some tools assess the impact of hair disorders on quality of life, including Hairdex¹², the
12 modified Dermatology Life Quality Index (DLQI), adapted DLQI¹³, and additional tools¹⁴
13 have been proposed. However, no tools specifically cater to patients experiencing CIA or EIA
14 outside the Chemotherapy-induced Alopecia Distress Scale (CADS). Recently, the CADS¹⁵,
15 measuring CIA-induced distress in patients with breast cancer, was developed and introduced
16 by Cho and colleagues¹⁶. CADS is the first validated tool to quantify the psychological
17 impact of CIA on breast cancer patients. Testing 25 items, 17 items, covering the four
18 domains ‘physical’ (2), ‘emotional’ (6), ‘activity’ (6), and ‘relationship’ (3) were identified
19 through exploratory factor analysis.

20 CADS was validated in a cohort of 305 Korean breast cancer patients and found reliable and
21 valid, with a coefficient alpha of 0.95 overall and 0.77-0.95 for the subdomains. Total scores
22 ranging from 0 to 51 and mean scores by domains were recorded. Higher scores represent
23 higher levels of distress. The availability of a total score allows for a simple understanding of
24 a patient’s alopecia-related distress. Subsequently, the values from each domain provide a

1 more detailed assessment of the experienced distress. It has been recognized as a crucial tool
2 in monitoring the CIA's impact on cancer patients. It has been translated and validated for
3 Chinese patients¹⁷ but not for English-speaking populations. Even more importantly, CADS
4 has not been validated for EIA, and a comparable tool for this population is missing. The
5 initial validation study's design could not assess responsiveness¹⁸, which is crucial in
6 understanding the longitudinal impact on patients over time¹⁹ and constitutes an essential
7 aspect of validation²⁰. We used a prospective cohort of patients receiving chemotherapy or
8 endocrine therapy for non-metastatic breast cancer²¹ to validate the English version of the
9 CADS scale.²¹ In addition, we aim to assess the responsiveness of the CADS, which was not
10 evaluated in the original study due to study design limitations¹⁹.

11

12 **METHODS**

13 **Participants**

14 We used cohort data from a single-center, prospective cohort study entitled *Chemotherapy-*
15 *Induced Hair Changes and Alopecia, Skin Aging and Nail Changes in Women with Non-*
16 *Metastatic Breast Cancer* (CHANCE study NCT02530177²¹). The CHANCE study was
17 conducted at Memorial Sloan Kettering Cancer Center to quantify the incidence of persistent
18 alopecia and alopecia in breast cancer patients receiving cytotoxic chemotherapy and
19 endocrine therapy, respectively. Subjects were eligible to participate if they were diagnosed
20 with breast cancer (ductal carcinoma in situ (DCIS), stage I to III), had no sign of metastasis,
21 and were expected to have cytotoxic chemotherapy and/or endocrine therapy. The study was
22 designed to enroll 100 patients in each of the five treatment cohorts for 500 patients who
23 were followed over time. Due to the nature of the various treatment types and individual
24 susceptibility, this included patients with G0-G2 alopecia.

25 Since the purpose of this study was the validation of CADS in patients with

1 chemotherapy and/or endocrine therapy, we used 256 patients with chemotherapy and/or
2 endocrine therapy who have completed their study visit at the completion of chemotherapy in
3 patients with chemotherapy, and at week 24 from baseline in patients with endocrine
4 treatment only. To test reliability, we used visits at 24 months and 30 months after enrollment
5 expecting only a slight change in the chemotherapy-induced alopecia distress and patients
6 who did not change hair status between the period. This number is lower than the target
7 enrolment as patients from the control cohort (pre-and post-menopausal women, assessed at
8 baseline only) were not evaluated, and patients with missing data points at either baseline or
9 specified endpoint were excluded.

10 All procedures were approved by the Institutional Review Board of Memorial Sloan
11 Kettering Cancer Center, New York, NY (IRB Number: 15-198 A(10), NCT02530177), and
12 all participants provided written informed consent before participation.

13

14 **Measurement**

15 The CADS is a psychometric scale for assessing the distress that breast cancer
16 patients experience because of CIA. Its reliability and validity were established with a cross-
17 sectional survey of 305 Korean women with breast cancer.¹⁶ Exploratory factor analysis and
18 confirmatory factor analysis yielded 17 items in four domains with good model fit, including
19 physical (two questions), emotional (six questions), daily activity (six questions), and
20 relationship (three questions) domains. The response is based on a 4-point Likert scale (0 =
21 not at all, 1 = a little, 2 = quite a bit, and 3 = very much). The CADS total score is calculated
22 by summing responses for all items, ranging from 0 to 51. A higher score indicates higher
23 distress. The English version of CADS used in this study has been translated and
24 linguistically validated by Dr. Cho (JC) using the standardized methodology recommended
25 by Functional Assessment of Chronic Illness Therapy multilingual translation (FACITtrans)

1 ²². JC's research team reviewed all documentation pertaining to the CADS translation,
2 including the item history and decisions about item rephrasing, before being finalized for
3 cognitive testing. No translation issues related to the response options, linguistics, and
4 conceptual equivalence to the original CADS measure, as intended, were reported. The
5 participants subsequently underwent cognitive debriefing for 30 min to evaluate
6 comprehension; ease of response; and acceptability of the terminology, phrasing, and
7 response options. Cognitive interviews were conducted by one oncology nurse and a
8 behavioral scientist. Cancer patients were recruited until saturation; 5 participated in the
9 cognitive interviews. The cognitive debriefing revealed that the participants generally
10 comprehended the CADS well.

11 We also evaluated the association between the CADS and standardized
12 phototrichogram data to confirm the construct validity (“known groups”). The objective data
13 included the number and thickness of hair and patients' reported satisfaction with hair.
14 Clinical characteristics such as demographic information of study participants were obtained
15 from electronic medical records.

16

17 **Statistical analysis**

18 *Item internal consistency*

19 Descriptive statistics were used to report participants' characteristics and the mean
20 and standard deviation (SD) of each item of the CADS. We calculated Cronbach's alpha to
21 test the internal consistency and reliability of the CADS. We expected a value greater than
22 0.75, which is the standard for defining the acceptable reliability of an instrument. At least
23 209 patients were required to estimate Cronbach's alpha of 0.75 with $\pm 5\%$ accuracy at 95%
24 confidence intervals in the 17-item CADS. ²³ This study had 256 patients, which was
25 sufficient. To further evaluate the test's internal consistency, we also estimated the corrected

1 item-rest correlation, which represents the correlation of the item with the rest of the total
2 score. Items exceeding a correlation of 0.40 are judged as ‘good.’²⁴

3 We initially attempted to use structural equation modeling (SEM) for the CFA but
4 encountered difficulties constraining secondary loadings to zero without compromising
5 model fit. In addition, because treating ordinal data as continuous in SEM would not be
6 appropriate, we adopted exploratory structural equation modeling (ESEM), which allows for
7 an unconstrained measurement model with all possible cross-loadings as free parameters.²⁵
8 This approach is identified through the specification of a rotation option. It provides standard
9 errors and fit statistics for freely estimated parameters, making it a suitable method for our
10 analysis in this study.

11 Several goodness-of-fit indices were used to evaluate the model fit, including the
12 comparative-fit-index (CFI), Tucker-Lewis Index (TLI), standardized root-mean-squared
13 residual (SRMR), and root mean square error of approximation (RMSEA). A CFI >0.9, TLI
14 >0.9, SRMR <0.08, and RMSEA <0.06 indicate a good fit for the data.²⁶

15

16 *Known-Group Validity*

17 We determined cross-sectional and longitudinal known-group validity using variables of
18 patients with and without chemotherapy and objective measures including the number of hair
19 and thickness of hair. Cross-sectional known-group validity independent t-tests were used to
20 evaluate whether CADS scores were different based on chemotherapy. In addition, the
21 correlation between CADS with the number of hair and thickness of hair shafts were assessed
22 using Pearson’s correlation, and we expected total scores to at least moderately correlate
23 ($0.30 \leq r \leq 0.70$).

24

25 *Reliability*

1 The test-retest reliability of the CADS was measured using the intra-class correlation
2 coefficient (ICC) using a two-way mixed model. A questionnaire is considered reliable at ICC
3 values > 0.70.²⁶

4 5 *Responsiveness*

6 Responsiveness is the capacity of the questionnaire to identify possible changes in the
7 construct associated with the clinical condition over time.²⁸ This responsiveness was
8 measured by the effect size (ES).²⁹ ES was calculated by the variation of the score in the
9 CADS between patients with and without satisfaction with hair growing or decreasing and no
10 change of satisfaction with hair growing by the standard deviation of the score. Based on the
11 previous studies^{9,30}, the following specific hypotheses were tested: 1) decreasing satisfaction
12 with hair growth would have a positive correlation of at least 0.5 with the increasing
13 emotional domain in CADS after treatment; 2) decreasing satisfaction with hair growth
14 would have a positive correlation of at least 0.2 with the increasing physical, activity, and
15 relationship domains in CADS after treatment; and 3) decreasing satisfaction with hair
16 growth will have a positive correlation of at least 0.2 with the increasing total score of CADS
17 after treatment.

18 The significance level was at $P < 0.05$ (two-sided), and all statistical analyses were
19 done using STATA software package 16 (STATA Corp., 4905 Lakeway Drive, College Station,
20 TX 77845 USA).

21

22 **RESULTS**

23 *Study participants*

1 The mean age was 53.1 years, and 30% were BC stage II or III. Among the study participants,
2 57.4% received chemotherapy (Table 1). On a scale of 0 to 51, the mean CADS score was 3.1
3 (SD = 5.3) and 5.9 (SD = 7.1) at baseline and cycle 8, respectively.

4

5 *Item internal consistency*

6 The Cronbach's alpha coefficients of 4 sub-domains in the CADS ranged from 0.50
7 to 0.88, indicating satisfactory internal consistency except for physical function. When any
8 items were removed, item-rest correlations varied from 0.18 to 0.74. While all the items had
9 generally accepted levels of item-rest correlation (≥ 0.40), the item "The area is itching" ($r =$
10 0.18), "The area is burning or prickling resulting pain." ($r = 0.31$), and "I have difficulty
11 doing personal care such as bath and make-up." ($r = 0.35$) had a relatively low correlation
12 with other items in the domain (Table 2). However overall CADS scale of Cronbach's alpha
13 coefficients was 0.91, indicating good reliability. The Cronbach's alpha coefficients were
14 0.89 and 0.86 in patients on chemotherapy and patients on endocrine therapy only,
15 respectively, and the CADS had acceptable reliability in both groups.

16

17 *Confirmatory factor analysis*

18 In confirmatory factor analysis, test statistics, degrees of freedom, and p values of the Chi-
19 square test were 2384.075, 136, and <0.01 . The goodness-of-fit indices for CADS (Figure 1)
20 were relatively high (CFI = 0.940, TLI = 0.890, SRMR = 0.041, and RMSEA = 0.084 (95%
21 CI = 0.071, 0.098)).

22 *Cross-sectional Known-Group Validity*

1 Compared to patients only on endocrine therapy, patients on chemotherapy were more likely
2 to have higher distress due to CIA (Table 2), and the difference was statistically significant (P
3 < 0.05). Overall, the highest distress item was “I am dissatisfied with my appearance.”
4 followed by “I always wear a wig or scarf to hide hair loss” (Table 2). The highest distress
5 items in the chemotherapy- and endocrine therapy group were “I always wear a wig or scarf
6 to hide hair loss” and “I am easily irritated and stressed,” respectively (Table 2).

7 In cross-sectional known group analysis using subjective measurement, the ES
8 between the with and without satisfaction with hair growth and higher emotional and activity
9 domain was 0.91 and 0.92, respectively. The satisfaction was strongly associated with a total
10 score of CADS (ES = 0.97) (Table 3). The differences in CADS score between patients with
11 and without satisfaction with hair growth were observed to be of large ES in both
12 chemotherapies (ES = 0.60) and endocrine therapy-only group (ES = 0.52) (Table 3).

13 Regarding the objective phototrichogram data, a moderate correlation was observed
14 between the total score of CADS, number of hair ($r = -0.33$), and thickness of hair shafts ($r =$
15 -0.44) at the completion of chemotherapy or 24 weeks after initiation of endocrine therapy.
16 Among the domains, the activity domain was more likely to have a higher correlation with
17 the number of hair ($r = -0.40$) and thickness of hair shafts ($r = -0.49$) (Table 4). The
18 correlation between CADS score and the number and thickness of hair was observed to be of
19 large ES in both chemotherapies (ES = 0.60) and endocrine therapy-only group (ES = 0.52)
20 (Table 3).

21

22 *Longitudinal Reliability and Responsiveness*

1 Among the patients who did not change hair status between 24 months and 30
2 months after enrollment, the ICC of CADS total score between 24 months and 30 months was
3 0.83 (95% CI 0.73, 0.89), which indicated satisfactory consistency.

4 In responsiveness based on the satisfaction with hair growing, the results in relation
5 to our hypotheses were as follows: 1) The ES between the decreasing satisfaction with hair
6 growing and increasing emotional domain was 0.49, which was in accordance with
7 hypothesis 1. 2), 3), and 4) The ES between the decreasing satisfaction and the average
8 change score of the physical, activity and relationship was 0.39, 0.57 and 0.20, which was in
9 accordance with hypotheses 2,3, and 4. 5) The correlation between decreasing satisfaction
10 with hair growing and CADS total score was 0.55, which was in accordance with hypotheses
11 5) (Table 3). There was moderate ES between decreasing satisfaction and change of CADS
12 score in both chemotherapy (ES = 0.30) and endocrine therapy-only group (ES = 0.50) (Table
13 3).

14 The correlation between the change in the total score of CADS and the difference in
15 the thickness of hair ($r = -0.35$) the observed correlation was moderate. The change in the
16 activity domain was also observed to have the highest correlation with the change in
17 objective measures (Table 4). Between the shift in the number and thickness of hair and the
18 change in CADS score, a moderate correlation was observed in chemotherapy (ES = 0.26),
19 but a weak correlation in the endocrine therapy-only group (Table 4).

20

21 **Discussion**

22

23 To fill an essential gap in measuring psychological distress associated with alopecia in cancer
24 patients, we validated the previously established CADS in a diverse English-speaking

1 population at Memorial Sloan Kettering Cancer Center in the United States. Additionally, we
2 aimed to expand the use of CADS to include patients treated with endocrine therapies. The
3 CADS, as demonstrated in this study, is reliable for administration in this non-Korean patient
4 population and can be used in patients with EIA in addition to CIA patients (Cronbach's alpha
5 0.86 and 0.89). Furthermore, we identified a moderate inverse correlation between hair count
6 and thickness assessed by phototrichogram with CADS. This further supports the validity of
7 CADS.

8 Interestingly, this study's mean total CADS score at baseline and completion of chemotherapy
9 or 24 weeks after initiation of endocrine therapy was 3.1 and 5.9, respectively. These total
10 scores are considerably lower than the median of 14 reported in the initial CADS validation
11 study¹⁸. Possible explanations for this finding include the inclusion of patients with EIA,
12 which tends to be less severe and leads to less psychological distress, and cultural differences
13 in the perception of female hair loss in general and during cancer treatment.

14 In terms of validity and reliability, all items had moderate or high loadings (>0.5),
15 supporting the factorability of the items in a development study. However, in our study, two
16 items in the physical domain revealed low loadings ("*The area is itching*" and "*The area is*
17 *burning or prickling, resulting in pain*"). This may be due to the status of our study
18 participants. Patients typically describe hot, itchy, tender, or tingly sensations on their scalp
19 (trichodynia) when actively losing hair from chemotherapy. However, in this study, CADS
20 was assessed at completion of chemotherapy when hair was expected to regrow. This may
21 explain the lower values in these items. To ensure the consistency of the CADS as an
22 international standardized instrument for psychometric analysis, we decided to maintain the
23 aforementioned items. Further studies will be required to modify these items and their
24 responsiveness for patients after completion of chemotherapy.

1 Regarding convergent validities using known group analysis, we found that
2 dissatisfaction with hair growing was associated with a higher total score of CADS (ES =
3 0.97). Emotional and activity stress domains were higher in patients who had dissatisfaction
4 with hair growth. In addition, we also found that with the objective phototrichogram data, a
5 moderate correlation was observed between the total score of CADS, number of hair ($r = -$
6 0.33), and thickness of hair shafts at completion of chemotherapy or 24 weeks after initiation
7 of endocrine therapy. The US Food and Drug Administration (FDA) has noted the need to
8 develop endpoints for clinical trials to measure aspects of alopecia that are important to
9 patients.²⁷ Considering the CADS was associated with hair density and hair thinning, which
10 was objectively quantified, as well as patient satisfaction, CADS could be a helpful
11 measurement tool as a valid patient-reported outcome response scale in clinical trials.

12 In responsiveness, the correlation between decreasing satisfaction with hair growing
13 and CADS total score was 0.55, and the minimal clinically meaningful difference of CADS
14 could be 5 points at complete chemotherapy. This means that in individual patients, a change
15 of 5 points, considered important by patients, cannot be distinguished from measurement
16 error with 95% confidence, so changes in individual patients should be interpreted with
17 caution.

18 The initial development of CADS has been a significant advancement in quantifying
19 the psychological impact of CIA¹⁶. However, using a questionnaire in different cultural
20 contexts and patient settings must be validated to ensure that the questionnaire applies to the
21 patients²⁸. This also implies that caution should be warranted when using CADS in similar
22 but not identical populations, e.g., western European patients in the future. An additional
23 potential limitation is the minor logistical burden associated with the administration and
24 scoring of the CADS, as well as time constraints for patients when used outside of clinical

1 trials. However, the ability to quantify the psychological distress of patients experiencing
2 chemotherapy-associated alopecia longitudinally will allow for better-shared decision-making
3 regarding alopecia treatment, prevention, and psychological support. The questionnaire's
4 advantages benefit patients overall and outweigh the logistical burdens.

5 *Limitations of this study:*

6 Limitations include single-center design. Further studies should validate CADS in different
7 patient populations with various cultures and languages and consider conducting international
8 multi-center studies. Second, we did not conduct a test-retest. However, the development
9 study¹⁵ and other validation study¹⁷ have already proven the reliability of the CADS, and we
10 expected our results to be similar to those in previous studies. Furthermore, when we
11 performed a reliability test using patients who did not experience a change in their hair
12 condition between two visits when the chemotherapy-induced alopecia status was relatively
13 consistent, the ICC was satisfied with the cut-off (ICC = 0.83). Lastly, since the item was a
14 categorical variable, the statistical interpretation was limited because approximate fit indexes
15 were initially developed for continuous outcomes.²⁹ However, studies support that ordinal
16 variables could be considered continuous variables in the structural equation model.²⁹ and the
17 model's goodness of fit in this study are acceptable.

18

19 *Clinical implications:*

20 The validated CADS is the first tool established for a diverse patient population in the United
21 States. Furthermore, including EIA patients expands this tool's validation to another patient
22 population.

23 *Conclusions:*

1 We have validated CADS as a reliable and responsive measurement of psychological distress
2 due to both CIA and EIA in a diverse Western population. We encourage its wide use in
3 research and clinical practice. Validation of CADS in additional linguistic, cultural, and
4 ethnic contexts will allow more patients to benefit from this psychometric tool.

5

6

1 **REFERENCE**

- 2 1 Trüeb RM. Chemotherapy-induced alopecia. *Seminars in cutaneous medicine and*
3 *surgery*. 28. No longer published by Elsevier; 2009:11-14.
- 4 2 Kang D, Kim IR, Choi EK et al. Permanent Chemotherapy-Induced Alopecia in
5 Patients with Breast Cancer: A 3-Year Prospective Cohort Study. *Oncologist* 2019; 24
6 (3): 414-420.
- 7 3 Boland V, Brady A-M, Drury A. The physical, psychological and social experiences of
8 alopecia among women receiving chemotherapy: An integrative literature review.
9 *European Journal of Oncology Nursing* 2020; 49: 101840.
- 10 4 McGarvey EL, Baum LD, Pinkerton RC et al. Psychological Sequelae and Alopecia
11 Among Women with Cancer. *Cancer Practice* 2001; 9 (6): 283-289.
- 12 5 Freites-Martinez A, Shapiro J, Chan D et al. Endocrine Therapy–Induced Alopecia in
13 Patients With Breast Cancer. *JAMA Dermatology* 2018; 154 (6): 670-675.
- 14 6 Moscetti L, Agnese Fabbri M, Sperduti I et al. Adjuvant aromatase inhibitor therapy
15 in early breast cancer: what factors lead patients to discontinue treatment? *Tumori*
16 2015; 101 (5): 469-473.
- 17 7 Gallicchio L, Calhoun C, Helzlsouer KJ. Aromatase inhibitor therapy and hair loss
18 among breast cancer survivors. *Breast Cancer Res Treat* 2013; 142 (2): 435-443.
- 19 8 Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on
20 quality of life among women with breast cancer: a literature review. *Psycho-oncology*
21 2008; 17 (4): 317-328.
- 22 9 Choi EK, Kim IR, Chang O et al. Impact of chemotherapy-induced alopecia distress
23 on body image, psychosocial well-being, and depression in breast cancer patients.
24 *Psycho-oncology* 2014; 23 (10): 1103-1110.
- 25 10 CTEP N. CTCAE v5.0. 2020.

- 1 https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick
2 [Reference_8.5x11.pdf](#).
- 3 11 Basch E, Reeve BB, Mitchell SA et al. Development of the National Cancer Institute's
4 Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse
5 Events (PRO-CTCAE). JNCI: Journal of the National Cancer Institute 2014; 106 (9).
- 6 12 Fischer TW, Schmidt S, Strauss B et al. HairdexEin Instrument zur Untersuchung der
7 krankheitsbezogenen Lebensqualität bei Patienten mit Haarerkrankungen. Der
8 Hautarzt 2001; 52 (3): 219-227.
- 9 13 Williamson D, Gonzalez M, Finlay AY. The effect of hair loss on quality of life. J Eur
10 Acad Dermatol Venereol 2001; 15 (2): 137-139.
- 11 14 Davis DS, Callender VD. Review of quality of life studies in women with alopecia.
12 International Journal of Women's Dermatology 2018; 4 (1): 18-22.
- 13 15 Cowley L, Heyman B, Stanton M et al. How women receiving adjuvant
14 chemotherapy for breast cancer cope with their treatment: a risk management
15 perspective. J Adv Nurs 2000; 31 (2): 314-321.
- 16 16 Cho J, Choi EK, Kim IR et al. Development and validation of Chemotherapy-induced
17 Alopecia Distress Scale (CADS) for breast cancer patients. Ann Oncol 2014; 25 (2):
18 346-351.
- 19 17 Cong W, Wu Y, Liu L et al. A Chinese version of the chemotherapy-induced alopecia
20 distress scale based on reliability and validity assessment in breast cancer patients.
21 Support Care Cancer 2020; 28 (9): 4327-4336.
- 22 18 Cho J, Choi EK, Kim IR et al. Development and validation of Chemotherapy-induced
23 Alopecia Distress Scale (CADS) for breast cancer patients. Annals of Oncology 2014;
24 25 (2): 346-351.
- 25 19 Mookink LB, Terwee CB, Patrick DL et al. The COSMIN study reached international

- 1 consensus on taxonomy, terminology, and definitions of measurement properties for
2 health-related patient-reported outcomes. *J Clin Epidemiol* 2010; 63 (7): 737-745.
- 3 20 de Boer MR, Terwee CB, de Vet HCW et al. Evaluation of Cross-sectional and
4 Longitudinal Construct Validity of Two Vision-related Quality of Life Questionnaires:
5 The LVQOL and VCM1. *Quality of Life Research* 2006; 15 (2): 233-248.
- 6 21 Lacouture ME, Freites-Martinez A, Patil S et al. The CHANCE study: A prospective,
7 longitudinal study of chemotherapy and hormonal therapy induced hair changes and
8 alopecia, skin aging and nail changes in women with non-metastatic breast cancer.
9 *Journal of Clinical Oncology* 2018; 36 (15_suppl): e12500-e12500.
- 10 22 Lent L, Hahn E, Eremenco S et al. Using cross-cultural input to adapt the Functional
11 Assessment of Chronic Illness Therapy (FACIT) scales. *Acta oncologica (Stockholm,
12 Sweden)* 1999; 38 (6): 695-702.
- 13 23 Bonett DG. Sample Size Requirements for Testing and Estimating Coefficient Alpha.
14 *Journal of Educational and Behavioral Statistics* 2002; 27 (4): 335-340.
- 15 24 Aiken LR. Book Reviews : Measuring Educational Achievement by Robert L. Ebel.
16 Englewood Cliffs, N. J.: Prentice-Hall, 1965. pp. xii + 481. *Educational and
17 Psychological Measurement* 1965; 25 (4): 1167-1169.
- 18 25 van Zyl LE, Ten Klooster PM. Exploratory Structural Equation Modeling: Practical
19 Guidelines and Tutorial With a Convenient Online Tool for Mplus. *Front Psychiatry*
20 2021; 12: 795672.
- 21 26 de Souza JA, Yap BJ, Wroblewski K et al. Measuring financial toxicity as a clinically
22 relevant patient-reported outcome: The validation of the COmprehensive Score for
23 financial Toxicity (COST). *Cancer* 2017; 123 (3): 476-484.
- 24 27 Food U, Administration D. The voice of the patient. A series of reports from the US
25 Food and Drug Administration's (FDA's) Patient-Focused Drug Development

1 Initiative. Lung Cancer Available from: <http://wayback> archive-it
2 org/7993/20171114193841/<https://www> fda
3 gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm353273 htm Accessed
4 February 2018; 28.

5 28 Tsang S, Royse CF, Terkawi AS. Guidelines for developing, translating, and
6 validating a questionnaire in perioperative and pain medicine. Saudi J Anaesth 2017;
7 11 (Suppl 1): S80-s89.


8 29 Muthén B. A general structural equation model with dichotomous, ordered categorical,
9 and continuous latent variable indicators. Psychometrika 1984; 49 (1): 115-132.

10
11

1 **Figure legends**

2 **Figure 1. Confirmatory factor analysis of Chemotherapy-induced Alopecia Distress**

3 **Scale items**



4

5

6 **Table 1. Patient characteristics and baseline measurements (N= 256)**

7

Characteristics	Overall (N= 256) N (%)	Sub-cohort	
		Chemotherapy (N = 147)	Endocrine therapy only (N = 109)
Age			
Mean (SD),	53.1 (11.4)	50.9 (11.5)	56.2 (10.6)
Race (N = 216)			
White	151 (69.9)	81 (66.4)	70 (74.5)
Black or African American	21 (9.7)	15 (12.3)	6 (6.4)
Latino/ Hispanic	16 (7.4)	12 (9.8)	4 (4.3)
Asian	17 (7.9)	9 (7.4)	8 (8.5)
Others	11 (5.1)	5 (4.1)	6 (6.4)
Disease stage at diagnosis			
DCIS	18 (7.0)	0	18 (16.5)
I	157 (61.3)	77 (52.4)	80 (73.4)
II	71 (27.7)	60 (40.8)	11 (10.1)
III	9 (3.5)	9 (6.1)	0
Unknown	1 (0.4)	1 (0.7)	0
Treatment modality			
Cytotoxic chemotherapy			
ddAC-T	73 (28.5)	73 (49.7)	
CMF	48 (18.8)	48 (32.7)	
Newer Combination Regimens	26 (10.2)	26 (17.7)	
Endocrine therapy			
Tamoxifen	46 (18.0)		46 (42.2)
Aromatase Inhibitor	63 (24.6)		63 (57.8)

8 *Patient who received chemotherapy

9

Table 2. Reliability of the Chemotherapy-Induced Alopecia Distress Scale (N= 256) Chemotherapy induce Alopecia Scale , CADS

Table 3. Known-group validity and Responsiveness validity of Chemotherapy-induced alopecia distress scale (CADS) subscale by patients with and without satisfaction with hair growing baseline and after treatment

	Total				Chemotherapy				Sub-cohort Endocrine therapy only			
	Without Satisfaction with hair growing	Satisfaction with hair growing	ES	P	Without Satisfaction with hair growing	Satisfaction with hair growing	ES	P	Without Satisfaction with hair growing	Satisfaction with hair growing	ES	P
Known-group validity												
Cycle 8/ Week 24/ End of Tx												
N (%)	85 (38.1)	138 (61.9)			71 (61.7)	44 (38.3)			14 (13.0)	94 (87.0)		
Physical	0.78 (0.97)	0.40 (0.69)	0.47	<0.01	0.86 (1.00)	0.55 (0.79)	0.35	0.08	0.36 (0.63)	0.31 (0.61)	0.08	0.78
Emotional	4.75 (3.87)	1.71 (3.04)	0.91	<0.01	5.18 (3.94)	3.02 (3.79)	0.56	<0.01	2.57 (2.62)	0.98 (2.09)	0.67	0.01
Activity	3.51 (3.41)	0.92 (2.09)	0.92	<0.01	4.10 (3.40)	2.34 (3.13)	0.54	<0.01	0.50 (1.16)	0.24 (0.70)	0.27	0.25
Relationship	0.92 (1.71)	0.32 (0.95)	0.43	<0.01	1.06 (1.80)	0.55 (1.21)	0.33	0.10	0.21 (0.80)	0.21 (0.79)	0.00	0.99
Total CADS	9.95 (8.13)	3.35 (5.58)	0.97	<0.01	11.20 (8.18)	6.45 (7.44)	0.60	<0.01	3.64 (3.88)	1.74 (3.34)	0.52	0.05
Responsiveness												
	Decreasing Satisfaction with hair growing	No change	ES	P	Decreasing Satisfaction with hair growing	No change	ES	P	Decreasing Satisfaction with hair growing	No change	ES	P
Change from baseline to End of Tx*												
N (%)	52 (33.3)	104 (66.7)			46 (53.5)	40 (46.5)			6 (7.2)	71 (92.2)		
Physical	0.44 (1.11)	0.05 (0.86)	0.39	0.02	0.50 (1.15)	0.06 (1.27)	0.36	0.11	0 (0.63)	0.04 (0.62)	0.07	0.87
Emotional	2.25 (4.14)	0.43 (3.28)	0.49	<0.01	2.54 (4.31)	1.27 (4.93)	0.27	0.23	0 (1.10)	0.04 (2.07)	0.03	0.96
Activity	2.31 (4.02)	0.48 (2.09)	0.57	<0.01	2.76 (3.96)	1.58 (3.35)	0.32	0.17	-1.17 (2.86)	-0.03 (0.68)	0.55	<0.01
Relationship	0.27 (2.36)	-0.11 (1.12)	0.20	0.19	0.39 (2.46)	0.12 (1.83)	0.12	0.60	-0.67 (1.03)	-0.21 (0.67)	0.52	0.13
Total CADS	5.27 (9.72)	0.86 (5.93)	0.55	<0.01	6.20 (9.88)	3.03 (9.67)	0.32	0.16	-1.83 (4.12)	-0.15 (2.38)	0.50	0.12

CADS, Chemotherapy-induced Alopecia Distress Scale; Effect Size, ES; Treatment, Tx

*Among patient with satisfaction with their hair at baseline

Table 4. Cross-sectional and Longitudinal correlation coefficients between scores of the Chemotherapy-Induced Alopecia Distress Scale (CADS), and number and thickness of hair before and after chemotherapy

	Total (N= 257)		Sub-cohort			
	Number of hair (N/cm ²)	Thickness of hair (mm)	Chemotherapy		Endocrine therapy only	
			Number of hair (N/cm ²)	Thickness of hair (mm)	Number of hair (N/cm ²)	Thickness of hair (mm)
Cross-sectional score						
Physical	-0.15**	-0.12*	-0.02	-0.03	-0.17	-0.06
Emotional	-0.27**	-0.36**	-0.05	-0.23**	-0.14	-0.00
Activity	-0.40**	-0.49**	-0.18*	-0.34**	-0.14	0.02
Relationship	-0.11	-0.23**	-0.00	-0.18*	0.02	0.04
Total CADS	-0.33**	-0.44**	-0.10	-0.30**	-0.15	0.02
Longitudinal change of score						
Physical	-0.06	-0.03	0.00	0.05	0.07	0.04
Emotional	-0.20**	-0.29**	-0.08	-0.22*	-0.06	0.09
Activity	-0.27**	-0.39**	-0.11	-0.28**	0.11	0.24*
Relationship	-0.07	-0.26**	-0.01	-0.24*	0.29**	0.26
Total CADS	-0.23**	-0.35**	-0.08	-0.26**	0.11	0.20

* P < 0.05

**P < 0.01




Figure 1

